Investors That Purchased FSD Pharma Securities May Have An Opportunity To Recover Their Financial Losses.

MJLegal

CANADA: Morganti & Co., P.C., a cross border shareholder’s rights law firm, has commenced a shareholder class action lawsuit against FSD Pharma Inc. for publishing investor documents containing misrepresentations of material fact about the status of its joint venture with Auxly Cannabis Group Inc. between September 29, 2018, and January 7 or February 6, 2019. The shareholders Read the full article…

FSD Pharma Announces Strategic Investment In Toronto’s Huge Shops

toronto

FSD Pharma Announces Strategic Investment in Huge Shops CANADA: FSD Pharma has completed a strategic investment of $1.3 million or just under 9.9% in Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with Chairman’s Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Read the full article…

FSD Pharma Achieves Over 4 Billion Shares Traded In First 6 Months

canadian-securities-exchange-launch-security-token-offerings-sto

CANADA:  FSD Pharma announced today that the Company has traded over four Billion Class B subordinate voting shares in its first six months of trading on the Canadian Securities Exchange. During the period of May 29, 2018 to November 29, 2018, the Company traded exactly 4,041,346,300 Class B subordinate voting shares on the CSE. This Read the full article…

FSD Pharma Appoints Top GW Pharmaceuticals Executive As Chief Executive Officer

FSD Pharma

Management addition comes as FSD accelerates specialty cannabinoid pharmaceutical global expansion strategy CANADA:  FSD Pharma announced today the appointment of Rupert Haynes as Chief Executive Officer. Mr. Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience having most recently held the position of Head of Global Marketing at GW Pharmaceuticals Read the full article…

FSD Pharma Announces Launch of IBS Clinical Study

beaker art

CANADA: FSD Pharma has announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics. The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy Read the full article…

FSD Pharma Begins Construction Of Heritage Museum & Flagship Dispensary In Ontario

FV Pharma

CANADA: FSD Pharma Inc. announced that construction has commenced of its heritage museum and flagship dispensary at the former Kraft plant in Cobourg, Ontario, headquarters of its wholly-owned subsidiary FV Pharma Inc. Local politicians and media will be in attendance at the ribbon-cutting ceremony on October 9, 2018 at 11:30 EST in Cobourg at the Head office Read the full article…

FSD Pharma Inks Saskatchewan Wholesale Supply MOU With High Tide Ventures

FSD PHARMA ENTERS INTO SASKATCHEWAN WHOLESALE SUPPLY MOU OF UP TO 5,000 KILOGRAMS WITH HIGH TIDE VENTURES

CANADA: FSD Pharma this week announced that its wholly-owned subsidiary, FV Pharma Inc. has entered into a non-binding memorandum of understanding with High Tide Ventures Inc. (“High Tide”) dated July 18, 2018 to supply the Saskatchewan market on a wholesale basis with up to 5,000 kilograms of cannabis products over the next year when available. FSD Pharma is Read the full article…

FSD Pharma Announces Acquisition To Expand In Newfoundland

Strategic investment of $40 million to bring economic benefits to province of Newfoundland

CANADA: FSD Pharma announced a binding agreement to purchase 51% of Atlantic Island Cannabis (to be renamed FSD Atlantic Pharma Inc.) effective July 4, 2018. The agreement involves a strategic investment of $40 million to drive production and sales of legal cannabis in the province of Newfoundland. In the first phase of the project, an indoor high quality 45,000 Read the full article…